Share on StockTwits

TearLab Corp (NASDAQ:TEAR) Director Richard Lindstrom sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of $4.61, for a total value of $23,050.00. Following the sale, the director now directly owns 86,238 shares of the company’s stock, valued at approximately $397,557. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

TEAR has been the subject of a number of recent research reports. Analysts at Roth Capital cut their price target on shares of TearLab Corp from $11.00 to $8.00 in a research note on Friday, May 9th. Analysts at Canaccord Genuity cut their price target on shares of TearLab Corp from $15.00 to $10.00 in a research note on Friday, May 9th. They now have a “buy” rating on the stock. One analyst has rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $13.25.

TearLab Corp (NASDAQ:TEAR) opened at 5.23 on Thursday. TearLab Corp has a 1-year low of $3.80 and a 1-year high of $15.18. The stock’s 50-day moving average is $4.73 and its 200-day moving average is $6.46. The company’s market cap is $175.6 million.

TearLab Corp (NASDAQ:TEAR) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.14) by $0.03. The company had revenue of $4.21 million for the quarter, compared to the consensus estimate of $4.76 million. During the same quarter in the prior year, the company posted ($0.30) earnings per share. The company’s quarterly revenue was up 70.4% on a year-over-year basis. On average, analysts predict that TearLab Corp will post $-0.57 earnings per share for the current fiscal year.

TearLab Corp. is an in-vitro diagnostic company. The Company is commercializing a tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.